Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aurion Biotech Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, MOLOYE, TITILAYO, who is located in 1 distinct art unit. The current prosecution activity is limited to this point of contact.
MOLOYE, TITILAYO is the busiest examiner with 1 pending office action. Because the portfolio's pending workload is not distributed, the company's immediate results depend on the specific feedback from this examiner and art unit. This centralized status simplifies the tracking of pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.3% | +48.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18815522 | CORNEAL ENDOTHELIAL CELL MARKER | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18815522 | CORNEAL ENDOTHELIAL CELL MARKER | MOLOYE, TITILAYO | 1632 | DP | Non-Final OA | — | Pending | Aug 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAurion Biotech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Titilayo Moloye has the most, with 1 of Aurion Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
